500672 Stock Overview
Novartis India Limited operates as a healthcare company in India.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Novartis India Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,026.20 |
| 52 Week High | ₹1,224.00 |
| 52 Week Low | ₹561.05 |
| Beta | 0.36 |
| 1 Month Change | -0.63% |
| 3 Month Change | 9.33% |
| 1 Year Change | 76.63% |
| 3 Year Change | 57.12% |
| 5 Year Change | 48.38% |
| Change since IPO | 159.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| 500672 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.8% | -0.1% | 1.8% |
| 1Y | 76.6% | 55.9% | 46.4% |
Return vs Industry: 500672 exceeded the Indian Pharmaceuticals industry which returned 55.3% over the past year.
Return vs Market: 500672 exceeded the Indian Market which returned 46.1% over the past year.
Price Volatility
| 500672 volatility | |
|---|---|
| 500672 Average Weekly Movement | 7.9% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 500672 has not had significant price volatility in the past 3 months.
Volatility Over Time: 500672's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | 67 | Vas Narasimhan | www.novartis.in |
Novartis India Limited operates as a healthcare company in India. It offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands; and neurosciences products under the Tegrital and Exelon brands. The company was incorporated in 1947 and is based in Mumbai, India.
Novartis India Limited Fundamentals Summary
| 500672 fundamental statistics | |
|---|---|
| Market cap | ₹25.34b |
| Earnings (TTM) | ₹955.30m |
| Revenue (TTM) | ₹3.30b |
26.5x
P/E Ratio7.7x
P/S RatioIs 500672 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 500672 income statement (TTM) | |
|---|---|
| Revenue | ₹3.30b |
| Cost of Revenue | ₹1.89b |
| Gross Profit | ₹1.41b |
| Other Expenses | ₹454.90m |
| Earnings | ₹955.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 10, 2024
| Earnings per share (EPS) | 38.69 |
| Gross Margin | 42.73% |
| Net Profit Margin | 28.95% |
| Debt/Equity Ratio | 1.2% |
How did 500672 perform over the long term?
See historical performance and comparison